Has Shalaine Corbilla received payments from drug or device companies?

Yes. Drug and device makers reported $21,966 in general payments to Shalaine Corbilla across 270 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shalaine Corbilla did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shalaine Corbilla come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shalaine Corbilla

Primary Care · la Mesa, CANPI 1134577216

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Sanofi at 58.0% of the total. 2025 is the largest year on record at $10,284, more than ten times the $23 reported in 2021. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,966in general payments, 2019–2025

Across 270 payments — averaging $81.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$13K
AstraZeneca$2K
Boehringer Ingelheim$2K
GSK$2K
Actelion Pharmaceuticals US, Inc.$400
Novo Nordisk$398
plus $2K from 24 others

What the payments were for

Consulting fees$8,74840%
Travel & lodging$2,0769%
Food & beverage$10,89050%
Education$2511%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	34	$12,746
AstraZeneca	59	$2,222
Boehringer Ingelheim	57	$2,183
GSK	42	$1,859
Actelion Pharmaceuticals US, Inc.	7	$400
Novo Nordisk	6	$398
Insmed, Inc.	15	$235
Merck	6	$233
United Therapeutics Corporation	2	$212
Grifols USA, LLC	9	$212
Sanofi-aventis U.S. LLC	2	$194
Amgen	3	$170
Pulmonx Corporation	2	$136
AbbVie	1	$125
Johnson & Johnson	1	$120
Ascend Therapeutics US, LLC	4	$90
Antares Pharma, Inc.	4	$88
Verona Pharma, Inc.	3	$63
Regeneron Healthcare Solutions, Inc.	1	$36
Millicent US Inc	2	$33
Harmony Biosciences LLC	1	$33
Genentech USA, Inc.	1	$28
Novartis	1	$26
Breas Medical, Inc.	1	$22
Pfizer	1	$20
E.r. Squibb & Sons, L.L.C.	1	$20
Gilead	1	$17
Endo Pharmaceuticals Inc.	1	$17
Therapeuticsmd, Inc.	1	$13
Avion Pharmaceuticals	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,966 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.

See all primary care providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	65	$54,867
Breztri AerosphereBudesonide/Glycopyr/Formoterol	19	$16,810
Breo ElliptaFluticasone/Vilanterol	11	$5,000
Albuterol Sulfate HfaAlbuterol Sulfate	29	$566
Fluticasone Propionate	31	$528
ProgesteroneProgesterone, Micronized	18	$343
Montelukast Sodium	29	$245
Prednisone	52	$207
Azithromycin	18	$97
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	11	$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta	$1,859	$59,86776 claims
AstraZenecaBreztri Aerosphere	$2,222	$16,81019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.

Other primary care in la Mesa

Leslie FletcherTorrance$1.8M
Hamideh PourzandLos Angeles$103K
Veronica RamirezSacramento$83K
Tyson FieldstedBakersfield$65K
Kathryn CooperSan Diego$31K
Paula StoddardHanford$22K
Ashley LoweSan Diego$19K
Vanessa LeeLong Beach$16K
Lynda TranHuntington Beach$16K
Pailai KingSan Diego$15K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →